More than 2% of circulating tumor plasma cells defines plasma cell leukemia - like multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F23%3AE0110195" target="_blank" >RIV/00843989:_____/23:E0110195 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/23:00130051 RIV/61988987:17110/23:A2402L2G RIV/00216208:11150/23:10449613 RIV/65269705:_____/23:00077019 RIV/00179906:_____/23:10449613

Result on the web

<a href="https://ascopubs.org/doi/pdf/10.1200/JCO.22.01226?role=tab" target="_blank" >https://ascopubs.org/doi/pdf/10.1200/JCO.22.01226?role=tab</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1200/JCO.22.01226" target="_blank" >10.1200/JCO.22.01226</a>

Result language

angličtina

Original language name

More than 2% of circulating tumor plasma cells defines plasma cell leukemia - like multiple myeloma

Original language description

Purpose: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by ? 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to ? 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. Methods: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. Results: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P < .001) and overall survival (14.6 v 33.6 months; P = .023) than patients with < 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. Conclusion: Our study uncovers that ? 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of clinical oncology

ISSN

0732-183X

e-ISSN

1527-7755

Volume of the periodical

41

Issue of the periodical within the volume

7

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

1383-1392

UT code for WoS article

000946592600009

EID of the result in the Scopus database

2-s2.0-85148964090